Cetuximab in the Treatment of Metastatic Colorectal Cancer: a Model-Based Cost-Effectiveness Analysis
作者： J. Norum
DOI: 10.1179/JOC.2006.18.5.532
关键词:
摘要: AbstractCetuximab (Erbitux®) has shown activity in patients with metastatic colorectal cancer (mCRC). To evaluate the cost-effectiveness of this drug combined irinotecan mCRC, a model-based analysis (CEA) was performed. Data on cetuximab obtained from Medline December 2004 and ASCO-meeting were analyzed for life years gained (LYG) regard to use monoclonal antibody (MAb). Norwegian prices as January 2005 employed. The LYG ranged between 1.7 2.0 years. median cost per patient treated calculated €34,256 € 45,764 yielding range 205,536 323,040. Sensitivity documented price survival gain be major factors influencing ratio. In conclusion, indicates promising, but very expensive antibody.
sci-hub.se 参考文章(19)
Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Investigational New Drugs. ,vol. 17, pp. 259- 269 ,(1999) , 10.1023/A:1006384521198
Tzong-Shin Tzai, Chung-Liang Ho, Hsiao-Sheng Liu, Shih-Huang Chan, Nan-Haw Chow, Expression Profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder Clinical Cancer Research. ,vol. 7, pp. 1957- 1962 ,(2001)
Charles Erlichman, Daniel J. Sargent, New Treatment Options for Colorectal Cancer The New England Journal of Medicine. ,vol. 351, pp. 391- 392 ,(2004) , 10.1056/NEJME048151
John Graham-Pole, Phase II Trial Annals of Internal Medicine. ,vol. 120, pp. 691- 691 ,(1994) , 10.7326/0003-4819-120-8-199404150-00013
D. Maxwell Parkin, Freddie Bray, Jacques Ferlay, Paola Pisani, Estimating the world cancer burden: Globocan 2000 International Journal of Cancer. ,vol. 94, pp. 153- 156 ,(2001) , 10.1002/IJC.1440
David S. Salomon, Ralf Brandt, Fortunato Ciardiello, Nicola Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies Critical Reviews in Oncology Hematology. ,vol. 19, pp. 183- 232 ,(1995) , 10.1016/1040-8428(94)00144-I
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
David Cunningham, Seppo Pyrhönen, Roger D James, Cornelis JA Punt, Tamas F Hickish, Reino Heikkila, Tom B Johannesen, Hans Starkhammar, Clare A Topham, Lucile Awad, Christian Jacques, Patrice Herait, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1413- 1418 ,(1998) , 10.1016/S0140-6736(98)02309-5
Daniel J. Hicklin, Lee M. Ellis, Harlan W. Waksal, Andrea T. Hooper, Marie C. Prewett, Rajiv Bassi, Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts Clinical Cancer Research. ,vol. 8, pp. 994- 1003 ,(2002)
J. Norum, J.A. Olsen, A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer Annals of Oncology. ,vol. 8, pp. 1081- 1087 ,(1997) , 10.1023/A:1008265614183